Dr. Connors received dual undergraduate degrees in Chemistry and Mathematics from Boston College, a master’s degree in Chemistry from Tufts University, and doctoral degree in Biochemistry from Boston University. She joined the Amyloidosis Center as a post-doctoral trainee in 1994, and obtained faculty appointments in the Departments of Biochemistry and Pathology & Laboratory Medicine in 1998 and 2009, respectively.
Dr. Connors focuses her basic science research on uncovering the protein and genetic determinants that underlie the formation of amyloid. The early stages of her career featured structural analyses of amyloid-causing transthyretin (TTR) mutants, mainly those causing cardiac dysfunction. More recently, her studies have been focused on wild-type TTR amyloidosis, an age-related disease now recognized as an under-appreciated cause of heart failure in the elderly. She has received continuous support from the NIH and foundation grants, as well as industry-sponsored research agreements, and has authored more than 100 peer-reviewed scholarly articles and book chapters.
In 2009, Dr. Connors played a major role in establishment of the Amyloid Pathology Diagnostic Testing Laboratory in the Amyloidosis Center, a CAP-accredited and CLIA-certified facility that offers histologic and molecular testing for amyloid. Dr. Connors teaches GMS classes on systemic amyloidosis, and has mentored more than 20 master’s, doctoral and postdoctoral students. She has served on multiple local, national and international committees, and is Director of the Amyloidosis Center Gerry Laboratory and Co-Director of the Amyloid Pathology Diagnostic Testing Laboratory.
- Associate Professor, Biochemistry, Boston University School of Medicine
- Member, Amyloidosis Center, Boston University
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
- Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences
- Boston University, PhD
- Tufts University, MS
- Boston College, BS
- Published on 4/30/2020
Dasari AKR, Hung I, Michael B, Gan Z, Kelly JW, Connors LH, Griffin RG, Lim KH. Structural Characterization of Cardiac Ex Vivo Transthyretin Amyloid: Insight into the Transthyretin Misfolding Pathway In Vivo. Biochemistry. 2020 May 19; 59(19):1800-1803. PMID: 32338497.
- Published on 12/2/2019
Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, Vellanki N, Hellawell J, Siddiqi OK, Fox J, Maurer MS, Ruberg FL. Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. J Card Fail. 2019 Dec 02. PMID: 31805416.
- Published on 7/15/2019
Staron A, Connors LH, Ruberg FL, Mendelson LM, Sanchorawala V. A new era of amyloidosis: the trends at a major US referral centre. Amyloid. 2019 Dec; 26(4):192-196. PMID: 31306033.
- Published on 6/12/2019
Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F. Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. Sci Rep. 2019 06 12; 9(1):8552. PMID: 31189919.
- Published on 4/9/2019
Yunis A, Doros G, Luptak I, Connors LH, Sam F. Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis. Am J Cardiol. 2019 07 01; 124(1):122-130. PMID: 31053293.
- Published on 1/1/2019
Boldbaatar B, Maenpaa E, Sikora Hanson J, Connors L. Analysis of the non-coding rs3764479 mutation in the proximal promoter of the transthyretin gene. Amyloid. 2019; 26(sup1):83-84. PMID: 31343312.
- Published on 1/1/2019
Torres-Arancivia C, Chang D, Zaia J, Connors LH. Structural studies of serum clusterin in ATTRwt amyloidosis. Amyloid. 2019; 26(sup1):51-52. PMID: 31343316.
- Published on 1/1/2019
Torres-Arancivia C, Connors LH. Effect of diflunisal on clusterin levels in ATTRwt amyloidosis. Amyloid. 2019; 26(sup1):49-50. PMID: 31343317.
- Published on 7/21/2018
Giadone RM, Rosarda JD, Akepati PR, Thomas AC, Boldbaatar B, James MF, Wilson AA, Sanchorawala V, Connors LH, Berk JL, Wiseman RL, Murphy GJ. A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid. 2018 Sep; 25(3):148-155. PMID: 30032658.
- Published on 6/25/2018
Klimtchuk ES, Prokaeva T, Frame NM, Abdullahi HA, Spencer B, Dasari S, Cui H, Berk JL, Kurtin PJ, Connors LH, Gursky O. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease. Proc Natl Acad Sci U S A. 2018 07 10; 115(28):E6428-E6436. PMID: 29941560.
View 84 more publications: View full profile at BUMC